Zobrazeno 1 - 10
of 228
pro vyhledávání: '"Marlies S. Wijsenbeek"'
Autor:
Rhiannon Green, Michael Baldwin, Nick Pooley, Kate Misso, Maureen PMH Rutten-van Mölken, Nina Patel, Marlies S. Wijsenbeek
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-28 (2024)
Abstract Background Cough remains a persistent symptom in patients with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). To inform future research, treatment and care models, we conducted the first systematic synthesis
Externí odkaz:
https://doaj.org/article/a8c73654bca84cbf807ffba8e167888e
Autor:
Jelle R. Miedema, Lieke J. de Jong, Vivienne Kahlmann, Ingrid M. Bergen, Caroline E. Broos, Marlies S. Wijsenbeek, Rudi W. Hendriks, Odilia B. J. Corneth
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background The treatment response to corticosteroids in patients with sarcoidosis is highly variable. CD4+ T cells are central in sarcoid pathogenesis and their phenotype in peripheral blood (PB) associates with disease course. We hypothesiz
Externí odkaz:
https://doaj.org/article/dff29a9ed1ac42d8b0a4d358ec5f44f2
Autor:
Elizabeth R. Volkmann, Christopher P. Denton, Martin Kolb, Marlies S. Wijsenbeek-Lourens, Claire Emson, Krischan Hudson, Anthony J. Amatucci, Oliver Distler, Yannick Allanore, Dinesh Khanna
Publikováno v:
European Respiratory Review, Vol 33, Iss 172 (2024)
Lysophosphatidic acid (LPA)-mediated activation of LPA receptor 1 (LPAR1) contributes to the pathophysiology of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). These diseases are associated with high morbid
Externí odkaz:
https://doaj.org/article/7dad0459aeb649318b278eb58358677c
Autor:
Iris G. van der Sar, Marlies S. Wijsenbeek, Gert-Jan Braunstahl, Jason O. Loekabino, Anne-Marie C. Dingemans, Johannes C. C. M. In ‘t Veen, Catharina C. Moor
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Introduction Interstitial lung disease (ILD) may be difficult to distinguish from other respiratory diseases due to overlapping clinical presentation. Recognition of ILD is often late, causing delay which has been associated with worse clini
Externí odkaz:
https://doaj.org/article/856fbac4a895450bbc2df9191dab5c58
Autor:
Gizal Nakshbandi, Catharina C. Moor, Katerina Antoniou, Vincent Cottin, Anna-Maria Hoffmann-Vold, Edwin A. Koemans, Michael Kreuter, Philip L. Molyneaux, Wim A. Wuyts, Marlies S. Wijsenbeek
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Pulmonary fibrosis (PF) is caused by a heterogeneous group of diseases, with a high inter-individual variability in disease trajectory. Identifying disease progression in patients with PF has impact on clinical management decision
Externí odkaz:
https://doaj.org/article/208e2af0e837454b93041009cf411eb9
Autor:
Toby M. Maher, Courtney Schiffman, Michael Kreuter, Catharina C. Moor, Steven D. Nathan, Judit Axmann, Paula Belloni, Monica Bengus, Frank Gilberg, Klaus-Uwe Kirchgaessler, Marlies S. Wijsenbeek
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-12 (2022)
Abstract Background Patients with interstitial lung disease (ILD) require regular physician visits and referral to specialist ILD clinics. Difficulties or delays in accessing care can limit opportunities to monitor disease trajectory and response to
Externí odkaz:
https://doaj.org/article/e408398a513e4a71a24021b423960045
Autor:
Jelle R. Miedema, Catharina C. Moor, Marcel Veltkamp, Sara Baart, Natascha S. L. Lie, Jan C. Grutters, Marlies S. Wijsenbeek, Rémy L. M. Mostard
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-6 (2022)
Abstract Background Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF. However, the safety and effectiveness of pirfenidone in
Externí odkaz:
https://doaj.org/article/c9a7d9f9f6c24148afb4b32c0839dc92
Autor:
Ganesh Raghu, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden, Lawrence A. Ho, Marlies S. Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E. Antin-Ozerkis, Keith C. Meyer, Michael Kreuter, Tracy Burgess, Nikhil Kamath, Francis Donaldson, Luca Richeldi
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-12 (2022)
Abstract Background Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-
Externí odkaz:
https://doaj.org/article/2c195c019cfe4de6992fd1e22d59cc6f
Autor:
Theodoros Karampitsakos, Phuong Phuong Diep, Daan W. Loth, Iftikhar Nadeem, Elene Khurtsidze, Marlies S. Wijsenbeek, Wim A. Wuyts, Elena Bargagli, Antoine Froidure, Paolo Spagnolo, Marcel Veltkamp, Maria Molina-Molina, Cormac McCarthy, Katerina M. Antoniou, Michael Kreuter, Catharina C. Moor
Publikováno v:
ERJ Open Research, Vol 9, Iss 2 (2023)
This article contains a selection of scientific highlights in the field of interstitial lung diseases (ILDs) presented at the hybrid European Respiratory Society International Congress 2022. Early Career Members of Assembly 12 summarise recent advanc
Externí odkaz:
https://doaj.org/article/60444a550cb94a2e93f6c54f5aa3d1a4
Autor:
G.D.Marijn Veerman, Sanne C. van der Werff, Stijn L.W. Koolen, Jelle R. Miedema, Esther Oomen-de Hoop, Sophie C. van der Mark, Prewesh P. Chandoesing, Peter de Bruijn, Marlies S. Wijsenbeek, Ron H.J. Mathijssen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 151, Iss , Pp 113101- (2022)
Nintedanib is an oral small-molecule kinase inhibitor and first-line treatment for idiopathic pulmonary fibrosis. Nintedanib is a substrate of the drug efflux transporter ABCB1. Green tea flavonoids --especially epigallocatechin gallate (EGCG)-- are
Externí odkaz:
https://doaj.org/article/61ba893b04ea4310801185ef0a82accf